Hopp til innhold
NHI.no
Annonse

Tardive dyskinesier: Behandling

Innhold i artikkelen

Det viktigste tiltaket er å forebygge tilstanden. Forekomsten av tardive dyskinesier kan reduseres ved å bruke laveste effektive dose av det antipsykotiske midlet over kortest mulig tid. Hvis det likevel oppstår tardive dyskinesier, må behandlingen med det utløsende midlet snarest reduseres eller stanses. Utfordringen blir ofte å finne en god alternativ behandling for den underliggende psykiske lidelsen. I noen tilfeller har behandling med betablokker (blodtrykksmedisin, eks. propranolol) blitt brukt for å dempe symptomene. En lang rekke andre medikamenter er også aktuelle å forsøke. 

Annonse

Dette dokumentet er basert på det profesjonelle dokumentet Medikamentind. motoriske forstyr . Referanselisten for dette dokumentet vises nedenfor

  1. Buckley N, Mc Manus P. Fatal toxicity of drugs used in treatment of psychotic illnesses. Br J Psychiatry 1998: 172; 461-4
  2. Lima AR, Soares-Weiser K, Bacalthchuk J, Barnes TRE. Benzodiazepines for neuroleptic-induced acute akathisia (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software. The Cochrane Library
  3. Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract. 2017. PMID: 29024264 PubMed
  4. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD000459. DOI: 10.1002/14651858.CD000459.pub2. DOI
  5. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD000209. DOI: 10.1002/14651858.CD000209.pub2. DOI
  6. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015; 4: CD010501. pmid:25866243 PubMed
  7. Tammenmaa I, McGrath J, Sailas EES, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000207. DOI: 10.1002/14651858.CD000207. DOI
  8. Soares KVS, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. The Cochrane Library
  9. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD000203. DOI: 10.1002/14651858.CD000203.pub3. DOI
  10. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD000206. DOI: 10.1002/14651858.CD000206.pub3. DOI
  11. Soares-Weiser K, Irving CB, Rathbone J. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD000208. DOI: 10.1002/14651858.CD000208. DOI
  12. Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 20;1:CD000205. doi: 10.1002/14651858.CD000205.pub3. (Review) PMID: 29352477 PubMed
Annonse
Annonse